Department of R&D, Amarna Therapeutics B.V , Leiden, The Netherlands.
Department of R&D, Amarna Therapeutics S.L , Sevilla, Spain.
Hum Vaccin Immunother. 2021 Jan 2;17(1):14-21. doi: 10.1080/21645515.2020.1757989. Epub 2020 May 15.
Viruses have evolved to efficiently express their genes in host cells, which makes them ideally suited as gene delivery vectors for gene and immunotherapies. Replication competent (RC) viral vectors encoding foreign or self-proteins induce strong T-cell responses that can be used for the development of effective cancer treatments. Replication-defective (RD) viral vectors encoding self-proteins are non-immunogenic when introduced in a host naïve for the cognate virus. RD viral vectors can be used to develop gene replacement therapies for genetic disorders and tolerization therapies for autoimmune diseases and allergies. Degenerative/inflammatory diseases are associated with chronic inflammation and immune responses that damage the tissues involved. These diseases therefore strongly resemble autoimmune diseases. This review deals with the use of RC and RD viral vectors for unraveling the pathogenesis of immune-related diseases and their application to the development of the next generation prophylactics and therapeutics for todays' major diseases.
病毒已经进化到能够在宿主细胞中高效表达其基因,这使它们成为基因和免疫疗法的理想基因传递载体。编码外来或自身蛋白的复制型(RC)病毒载体可诱导强烈的 T 细胞反应,可用于开发有效的癌症治疗方法。在对同源病毒呈 naive 状态的宿主中,编码自身蛋白的复制缺陷型(RD)病毒载体不具有免疫原性。RD 病毒载体可用于开发用于遗传疾病的基因替代疗法和用于自身免疫性疾病和过敏的耐受疗法。退行性/炎症性疾病与慢性炎症和免疫反应有关,这些反应会损害涉及的组织。因此,这些疾病与自身免疫性疾病非常相似。本综述讨论了 RC 和 RD 病毒载体在阐明与免疫相关疾病的发病机制及其在开发当今主要疾病的下一代预防和治疗方法中的应用。